Modality
Peptide
MOA
VEGFi
Target
CGRP
Pathway
Hedgehog
CML
Development Pipeline
Preclinical
~Feb 2012
→ ~May 2013
Phase 1
~Aug 2013
→ ~Nov 2014
Phase 2
~Feb 2015
→ ~May 2016
Phase 3
~Aug 2016
→ ~Nov 2017
NDA/BLA
~Feb 2018
→ ~May 2019
Approved
Aug 2019
→ Dec 2025
ApprovedCurrent
NCT04998820
74 pts·CML
2019-08→2025-12·Active
74 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2025-12-034mo agoPh3 Readout· CML
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
Approved
Active
Catalysts
Ph3 Readout
2025-12-03 · 4mo ago
CML
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04998820 | Approved | CML | Active | 74 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP |